Seqirus to Begin Dedicated sa-mRNA Program
Seqirus is one of the world’s largest influenza vaccine companies, working to develop new vaccines every single year. Recently, this New Jersey-based company has announced plans to expand and accelerate their capabilities to develop next-gen self amplifying mRNA (sa-mRNA) vaccines. To achieve this goal, they will create a dedicated sa-mRNA program.
Last year the FDA green lit Audenz for the protection against influenza A (H5N1) in the event of a pandemic and won approval for Fluad Quadrivalent just three weeks later. This is the first and only quadrivalent adjuvanted flu vaccine to help protect adults over 65 years of age. Shortly after, their Flucelvax Quadrivalent was approved for a broader set of patients (ages two and up).
mRNA has been a notably well researched topic, but its implication and authorization of use in vaccines came with research done to fight COVID-19. mRNA based vaccines work by providing instructions to cells to make a protein that stimulates the immune response to fight future infections. Seqirus’ sa-mRNA tech also teaches the body to replicate mRNA, taking it a step further and amplifying the amount of protein made. This development suggests that the future of vaccines may be smaller doses, less negative reaction, and higher efficacy.
Seqirus is already developing multiple sa-mRNA-based influenza vaccine candidates with promising preclinical results but are hoping their dedicated sa-mRNA program will speed this along. If all goes well, they may even have clinical trials beginning for both seasonal and pandemic influenza vaccine candidates in the second half of 2022.
Are you developing new software for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
